Af­ter M&A fell through, Ther­a­peu­tic­sMD sells hor­mone ther­a­py, con­tra­cep­tive ring for $140M cash plus roy­al­ties

Ther­a­peu­tic­sMD, a women’s health com­pa­ny whose one-time bil­lion-dol­lar val­u­a­tion seems a dis­tant mem­o­ry as its block­buster as­pi­ra­tions pe­tered out, is fi­nal­ly cash­ing out.

Aus­tralia’s Mayne Phar­ma is pay­ing $140 mil­lion up­front to li­cense es­sen­tial­ly Ther­a­peu­tic­sMD’s whole port­fo­lio, in­clud­ing two pre­scrip­tion drugs that treat con­di­tions re­lat­ing to menopause, a con­tra­cep­tive vagi­nal ring as well as its pre­scrip­tion pre­na­tal vi­t­a­min brands.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.